Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 162-169

  Lv, Jianxin ^b   Fu, Ziyi ^a   Shi, Min ^b   Xia, Kai ^d   Ji, Chenbo ^a   Xu, Pengfei ^a   Lv, Mingming ^a   Pan, Bo ^b   Dai, Luxian ^b   Xie, Hui ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d JIANGYIN PEOPLE S HOSPITAL   (China)

Author keywords

Breast cancer; Chemoresistance; Has miR 760; Microarray

Indexed keywords

ABC TRANSPORTER A1; DOXORUBICIN; GUANINE NUCLEOTIDE BINDING PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; MICRORNA 760; NUCLEIC ACID; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; MIRN760 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CELL CYCLE; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE ONTOLOGY; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LENTIVIRINAE; METABOLISM;

BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; HUMANS; LENTIVIRUS; MCF-7 CELLS; MICRORNAS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84922210212     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.11.028     Document Type: Article

References (49)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol 2013, 2013:290568.
3. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
4. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007, 10:59-67.
5. Farazi T.A., Hoell J.I., Morozov P., Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013, 774:1-20.
6. Lv K., Liu L., Wang L., Yu J., Liu X., Cheng Y., et al. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS ONE 2012, 7:e40008.
7. Zhong S., Li W., Chen Z., Xu J., Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013, 531:8-14.
8. Bockhorn J., Dalton R., Nwachukwu C., Huang S., Prat A., Yee K., et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013, 4:1393.
9. Korner C., Keklikoglou I., Bender C., Worner A., Munstermann E., Wiemann S. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J Biol Chem 2013, 288:8750-8761.
10. Wang H., Tan G., Dong L., Cheng L., Li K., Wang Z., et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE 2012, 7:e34210.
11. Jiao X., Zhao L., Ma M., Bai X., He M., Yan Y., et al. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat 2013, 139:717-730.
12. Manavalan T.T., Teng Y., Litchfield L.M., Muluhngwi P., Al-Rayyan N., Klinge C.M. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS ONE 2013, 8:e62334.
13. Kopp F., Oak P.S., Wagner E., Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE 2012, 7:e50469.
14. Jung E.J., Santarpia L., Kim J., Esteva F.J., Moretti E., Buzdar A.U., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118:2603-2614.
15. Ma M.T., He M., Wang Y., Jiao X.Y., Zhao L., Bai X.F., et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett 2013, 339:107-115.
16. Hu H., Li S., Cui X., Lv X., Jiao Y., Yu F., et al. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 2013, 288:10973-10985.
17. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008, 68:1471-1477.
18. Chen G.Q., Zhao Z.W., Zhou H.Y., Liu Y.J., Yang H.J. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 2010, 27:406-415.
19. Kutanzi K.R., Yurchenko O.V., Beland F.A., Checkhun V.F., Pogribny I.P. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2011, 2:171-185.
20. Nassirpour R., Mehta P.P., Baxi S.M., Yin M.J. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS ONE 2013, 8:e62170.
21. Chen K., Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Gen 2007, 8:93-103.
22. Cicatiello L., Mutarelli M., Grober O.M., Paris O., Ferraro L., Ravo M., et al. Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 2010, 176:2113-2130.
23. Jianxin Lv, Kai Xia, Pengfei Xu, Erhu Sun, Jingjing Ma, Sheng Gao, Qian Zhou, Min Zhang, Fengliang Wang, Fei Chen, Ping Zhou, Ziyi Fu, Hui Xie miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014, doi:10.1016/j.biopha.2014.09.011.
24. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
25. Wang Q., Huang Z., Ni S., Xiao X., Xu Q., Wang L., et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS ONE 2012, 7:e44398.
26. Kim S.Y., Lee Y.H., Bae Y.S. MiR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells. Biochem Biophys Res Commun 2012, 429:173-179.
27. Lee Y.-H., Kim S.Y., Bae Y.-S. Upregulation of miR-760 and miR-186 Is Associated with Replicative Senescence in Human Lung Fibroblast Cells. Mol Cells 2014, 37:620.
28. Iwaya T., Fukagawa T., Suzuki Y., Takahashi Y., Sawada G., Ishibashi M., et al. Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer. Clin Cancer Res 2013, 19:6438-6449.
29. Chen K.G., Sikic B.I. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012, 18:1863-1869.
30. Clarke R., Leonessa F., Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005, 32:S9-S15.
31. Park S., Shimizu C., Shimoyama T., Takeda M., Ando M., Kohno T., et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006, 99:9-17.
32. Zhu Y., Yu F., Jiao Y., Feng J., Tang W., Yao H., et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011, 17:7105-7115.
33. Harris W., Ali H., Sarah L., Xinmei C., Amadeo P.M., Zhixiang W. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. BMC Cancer 2014, 14:37.
34. Tamaki A., Ierano C., Szakacs G., Robey R.W., Bates S.E. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011, 50:209-232.
35. Pratt S., Shepard R.L., Kandasamy R.A., Johnston P.A., Perry W., Dantzig A.H. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol ancer Ther 2005, 4:855-863.
36. Adnane J., Muro-Cacho C., Mathews L., Sebti S.M., Munoz-Antonia T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res 2002, 8:2225-2232.
37. Mazieres J., Antonia T., Daste G., Muro-Cacho C., Berchery D., Tillement V., et al. Loss of RhoB expression in human lung cancer progression. Clin Cancer Res 2004, 10:2742-2750.
38. Medale-Giamarchi C., Lajoie-Mazenc I., Malissein E., Meunier E., Couderc B., Berge Y., et al. RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Res 2013, 15:R6.
39. Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
40. Le Jan S., Amy C., Cazes A., Monnot C., Lamande N., Favier J., et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003, 162:1521-1528.
41. Huang R.-L., Teo Z., Chong H.C., Zhu P., Tan M.J., Tan C.K., et al. ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. Blood 2011, 118:3990-4002.
42. Zhu P., Tan M.J., Huang R.L., Tan C.K., Chong H.C., Pal M., et al. Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell 2011, 19:401-415.
43. Verine J., Lehmann-Che J., Soliman H., Feugeas J.-P., Vidal J.-S., Mongiat-Artus P., et al. Determination of Angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS ONE 2010, 5.
44. Verine J., Lehmann-Che J., Soliman H., Feugeas J.P., Vidal J.S., Mongiat-Artus P., et al. Determination of Angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS ONE. 2010, 5.
45. Nakayama T., Hirakawa H., Shibata K., Nazneen A., Abe K., Nagayasu T., et al. Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis. Oncol Rep 2011, 25:929-935.
46. Hu Z.Y., Fan C., Livasy C., He X.P., Oh D.S., Ewend M.G., et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 2009, 7.
47. Mannelqvist M., Stefansson I.M., Bredholt G., Bo T.H., Oyan A.M., Jonassen I., et al. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 2011, 178:861-871.
48. Nakayama T., Hirakawa H., Shibata K., Abe K., Nagayasu T., Taguchi T. Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion. Oncol Rep 2010, 24:599-606.
49. Adhikary T., Brandt D.T., Kaddatz K., Stockert J., Naruhn S., Meissner W., et al. Inverse PPARbeta/delta agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion. Oncogene 2013, 32:5241-5252.